1887

Abstract

Bloodstream infections due to species are important complications in severely ill hospitalized patients. This study presents data on species distribution and antifungal susceptibility profiles of bloodstream isolates obtained from Kuwait during a 10-year period. All the bloodstream isolates were identified to species level by the germ tube test and carbohydrate assimilation profile using the VITEK 2 yeast identification system. Using E-test strips for amphotericin B, fluconazole, 5-flucytosine and voriconazole, MICs were determined on RPMI agar supplemented with 2 % glucose. The MIC breakpoints for resistance were based on Clinical and Laboratory Standards Institute criteria or those published by reference laboratories, and were as follows: amphotericin B, >1 μg ml; fluconazole, ⩾64 μg ml; 5-flucytosine, ⩾32 μg ml; and voriconazole, 4 μg ml. In all, 607 bloodstream yeast isolates were obtained over the past 10 years in Kuwait. was the predominant species (39.5 %), followed by (30.6 %), (12.4 %), (5.6 %) and (1.6 %). All , and isolates were susceptible to amphotericin B. Of 186 isolates of tested, only four (2 %) exhibited an MIC for amphotericin B of >1 μg ml. Resistance to fluconazole was observed in nine (3.8 %) isolates, two (5.8 %) isolates and four (40 %) isolates. Resistance to 5-flucytosine was observed in two (0.8 %) isolates, seven (9.3 %) isolates, three (1.6 %) isolates and all ten (100 %) isolates. All the isolates of , , , and were susceptible to voriconazole, including those resistant to fluconazole. Although amphotericin B and fluconazole are widely used in clinical practice in Kuwait, resistance to these drugs remained low.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46817-0
2007-02-01
2019-11-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/2/255.html?itemId=/content/journal/jmm/10.1099/jmm.0.46817-0&mimeType=html&fmt=ahah

References

  1. Ahmad, S., Khan, Z., Mustafa, A. S. & Khan, Z. U. ( 2002; ). Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol 40, 2483–2489.[CrossRef]
    [Google Scholar]
  2. Ahmad, S., Khan, Z., Mustafa, A. S. & Khan, Z. U. ( 2003; ). Epidemiology of Candida colonization in an intensive care unit of a teaching hospital in Kuwait. Med Mycol 41, 487–493.[CrossRef]
    [Google Scholar]
  3. Al-Essa, M., Khan, Z. U., Rashwan, N. & Kazi, A. ( 2000; ). Pattern of candidemia in the newborn: a study from Kuwait. Med Princ Pract 9, 174–180.[CrossRef]
    [Google Scholar]
  4. Al-Jasser, A. M. & Elkhizzi, N. A. ( 2004; ). Distribution of Candida species among bloodstream isolates. Saudi Med J 25, 566–569.
    [Google Scholar]
  5. Alonso-Valle, H., Acha, O., Garcia-Palomo, J. D., Farinas-Alvarez, C., Fernandez-Mazarrasa, C. & Farinas, M. C. ( 2003; ). Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 22, 254–257.
    [Google Scholar]
  6. Barchiesi, F., Arzeni, D., Caselli, F. & Scalise, G. ( 2000; ). Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother 45, 408–409.[CrossRef]
    [Google Scholar]
  7. Blot, S. I., Vandewoude, K. H., Hoste, E. A. & Colardyn, F. A. ( 2002; ). Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 113, 480–485.[CrossRef]
    [Google Scholar]
  8. Bukharie, H. A. ( 2002; ). Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 153, 195–198.[CrossRef]
    [Google Scholar]
  9. Eggimann, P., Garbino, J. & Pittet, D. ( 2003; ). Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3, 685–702.[CrossRef]
    [Google Scholar]
  10. Ellis, M., Hedstrom, U., Jumaa, P. & Bener, A. ( 2003; ). Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 41, 521–528.[CrossRef]
    [Google Scholar]
  11. Gudlaugsson, O., Gillespie, S., Lee, K., Vande Berg, J., Hu, J., Messer, S., Herwaldt, L., Pfaller, M. A. & Diekema, D. ( 2003; ). Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37, 1172–1177.[CrossRef]
    [Google Scholar]
  12. Hobson, R. P. ( 2003; ). The global epidemiology of invasive Candida infections – is the tide turning? J Hosp Infect 55, 159–168.[CrossRef]
    [Google Scholar]
  13. Jarvis, W. R. ( 1995; ). Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20, 1526–1530.[CrossRef]
    [Google Scholar]
  14. Khan, Z. U. & Chugh, T. D. ( 2000; ). Invasive fungal infections in Kuwait: a retrospective study. Indian J Chest Dis Allied Sci 42, 279–287.
    [Google Scholar]
  15. Khan, Z. U., Ahmad, S., Mokaddas, E. & Chandy, R. ( 2004; ). Simplified sunflower (Helianthus annuus) seed agar for differentiation of Candida dubliniensis from Candida albicans. Clin Microbiol Infect 10, 590–592.[CrossRef]
    [Google Scholar]
  16. Lu, J. J., Lee, S. Y. & Chiueh, T. S. ( 2004; ). In vitro antifungal susceptibility testing of Candida blood isolates and evaluation of the E-test method. J Microbiol Immunol Infect 37, 335–342.
    [Google Scholar]
  17. Medoff, G. & Kobayashi, G. S. ( 1980; ). Strategies in the treatment of systemic fungal infections. N Engl J Med 302, 145–155.[CrossRef]
    [Google Scholar]
  18. Mokaddas, E. M., Ramadan, S. A., Abo el-Maaty, S. H. & Sanyal, S. C. ( 2000; ). Candidemia in pediatric surgery patients. J Chemother 12, 332–338.[CrossRef]
    [Google Scholar]
  19. Morgan, J. ( 2005; ). Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep 7, 429–439.[CrossRef]
    [Google Scholar]
  20. Nampoory, M. R., Khan, Z. U., Johny, K. V., Constandi, J. N., Gupta, R. K., Al-Muzairi, I., Samhan, M., Mozavi, M. & Chugh, T. D. ( 1996; ). Invasive fungal infections in renal transplant recipients. J Infect 33, 95–101.[CrossRef]
    [Google Scholar]
  21. National Committee for Clinical Laboratory Standards ( 2002; ). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard (M27-A2). Wayne, PA: National Committee for Clinical Laboratory Standards.
  22. Osoba, A. O., Al-Mowallad, A. W., McAlear, D. E. & Hussein, B. A. ( 2003; ). Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J 24, 1060–1063.
    [Google Scholar]
  23. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A. & other authors ( 2003a; ). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47, 3149–3154.[CrossRef]
    [Google Scholar]
  24. Ostrosky-Zeichner, L., Oude Lashof, A. M., Kullberg, B. J. & Rex, J. H. ( 2003b; ). Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22, 651–655.[CrossRef]
    [Google Scholar]
  25. Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B. & Wenzel, R. P. ( 1998; ). National surveillance of nosocomial bloodstream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 31, 327–332.[CrossRef]
    [Google Scholar]
  26. Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A. & The Sentry Participant Group ( 2001; ). International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39, 3254–3259.[CrossRef]
    [Google Scholar]
  27. Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. & Diekema, D. J. ( 2002; ). In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46, 3518–3521.[CrossRef]
    [Google Scholar]
  28. Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L. & Hollis, R. J. ( 2003; ). Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and E-test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41, 1440–1446.[CrossRef]
    [Google Scholar]
  29. Pfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J. & Diekema, D. J. ( 2005; ). Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 43, 5208–5213.[CrossRef]
    [Google Scholar]
  30. Quindos, G., Ruesga, M. T., Martin-Mazuelos, E., Salesa, R., Alonso-Vargas, R., Carrillo-Munoz, A. J., Brena, S., San Millan, R. & Ponton, J. ( 2004; ). In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 21, 63–69.
    [Google Scholar]
  31. Rennert, G., Rennert, H. S., Pitlik, S., Finkelstein, R. & Kitzes-Cohen, R. ( 2000; ). Epidemiology of candidemia – a nationwide survey in Israel. Infection 28, 26–29.[CrossRef]
    [Google Scholar]
  32. Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G. & other authors ( 1997; ). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24, 235–247.[CrossRef]
    [Google Scholar]
  33. Sanglard, D. & Odds, F. C. ( 2002; ). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2, 73–85.[CrossRef]
    [Google Scholar]
  34. Scholer, H. J. ( 1980; ). Flucytosine. In Antifungal Chemotherapy, pp. 35–106. Edited by D. C. E. Speller. Chichester, UK: Wiley.
  35. Simor, A. E., Goswell, G., Louie, L., Lee, M. & Louie, M. ( 1997; ). Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test. Eur J Clin Microbiol Infect Dis 16, 693–697.[CrossRef]
    [Google Scholar]
  36. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A. & Gaynes, R. P. ( 2002; ). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35, 627–630.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46817-0
Loading
/content/journal/jmm/10.1099/jmm.0.46817-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error